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ABSTRACT 
Objectives: This study aimed to assess the antiviral properties of a unique lectin 
(NICTABA) produced by the tobacco plant, Nicotiana tabacum.  
Methods: Cellular assays were used to investigate the antiviral activity of NICTABA 
and Urtica dioica agglutinin (UDA). Surface plasmon resonance (SPR) studies were 
performed to study the sugar specificity and the interactions of both lectins with the 
envelope glycoproteins of HIV-1.  
Results: The GlcNAc-binding lectins exhibited broad-spectrum activity against 
several families of enveloped viruses including influenza A/B, DENV2, HSV-1/2 and 
HIV-1/2. The IC50 of NICTABA for various HIV-1 strains, clinical isolates and HIV-
2 assessed in PBMCs ranged from 5 to 30 nM. Furthermore, NICTABA inhibited 
syncytium formation between persistently HIV-1-infected T-cells and uninfected 
CD4+ T lymphocytes and prevented DC-SIGN-mediated HIV-1 transmission to CD4+ 
target T lymphocytes. However, unlike many other antiviral carbohydrate-binding 
agents (CBAs) described so far, NICTABA did not block HIV-1 capture to DC-
SIGN+ cells and it did not interfere with the binding of the human mAb 2G12 to 
gp120. SPR studies with HIV-1 envelope glycoproteins showed that the affinity of 
NICTABA for gp120 and gp41 was in the low nanomolar range. Specific binding of 
NICTABA to gp120 could be prevented in the presence of a GlcNAc trimer but not of 
mannose trimers. NICTABA displayed no antiviral activity to non-enveloped viruses.  
Conclusions: Since CBAs possess a high genetic barrier for the development of viral 
resistance and NICTABA’s broad antiviral activity profile, this CBA may qualify as a 
potential antiviral candidate with a pleiotropic mode of action aimed at targeting the 
entry of enveloped viruses.  
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INTRODUCTION 
Viruses such as immunodeficiency virus (HIV), herpes simplex virus (HSV), 
influenza virus and hepatitis C virus (HCV) contain highly glycosylated proteins in 
their envelope. The HIV envelope protein gp120 is among the most heavily 
glycosylated proteins with almost 50% of its molecular weight being due to the 
presence of N-linked glycans.1,2 These glycans play an important role in the 
conformation of the envelope during synthesis and in viral transmission and 
subsequent infection.3-7 They also function as a shield to reduce the accessibility of 
the immunogenic protein core in order to prevent an efficient immune response.8-11 
Given the important structural and functional role of the viral envelope glycans, 
various carbohydrate-binding agents (CBAs) have been investigated for their potential 
to interfere with virus infection. In fact, CBAs have been proposed as a novel 
interesting class of antiviral drugs since they have been shown to have the capacity to 
inhibit (i) infection of cells by cell-free virus particles, (ii) the interaction between 
HIV-infected leukocytes and uninfected CD4+ cells, but also (iii) the capture of virus 
by DC-SIGN-expressing dendritic cells and macrophage mannose receptor (MMR)-
expressing macrophages12,13 and (iv) transmission of such captured virus to uninfected 
CD4+ T lymphocytes.14  
Because these agents block both entry and transmission of the virus, they 
would qualify as potent antiviral compounds with a pleiotropic mode of action. 
Several CBAs have therefore been studied more in detail for their antiviral 
properties.12,15-24 It has been shown that apart from their ability to prevent virus 
infection, capture and transmission, they are also able to force the virus to delete N-
glycosylation sites in their envelope after prolonged drug exposure. Indeed, after 
prolonged exposure of HIV-1 gp120 to escalating doses of a broad variety of CBAs 
(i.e., HHA, GNA, CV-N, 2G12, AH, MVN, PRM-S, GRFT or UDA), up to eight or 
nine N-glycosylation sites were deleted in the envelope of such mutant virus strains.25-
29 This implies a high genetic barrier for CBA treatment of viral infections since often 
more than 3 to 5 N-glycan deletions in the HIV gp120 are required to afford a 
significant phenotypic resistance to CBAs. Also, the uncovering of previously hidden 
immunogenic epitopes on the surface of the virion by the glycan deletions may trigger 
an immune response against these epitopes. It has indeed been shown that mutant 
HIV-1 strains that have several N-glycan deletions in their envelope, are more prone 
to neutralizing antibodies directed against gp120.11,14,30 For this reason the CBAs 
display a unique combination of antiviral mechanisms. A specific subgroup of CBAs 
are lectins.  Although lectins from natural origin have garnered much interest due to 
their specific interaction with carbohydrates and their strong antiviral properties, 
many hurdles have hampered the translation of their preclinical success. Firstly, 
lectins as a therapeutic strategy must overcome the issues posed by their protein 
nature, more specifically their sensitivity to proteolytic degradation, their large size, 
their short half-live and potential immunogenicity. Secondly, large-scale production 
and purification of these natural products is very costly and technically challenging. 
However, computational methods (e.g., EpiSweep) are currently available that aid in 
the design of immunotolerant therapeutic proteins with preserved structural 
properties.31 Furthermore, low molecular weight synthetic compounds with lectin-like 
properties could be an alternative solution for these problems. Pradimicin-A, 
pradimicin-S and benanomicin-A have also shown to have antiviral activities and 
represent the first prototype drugs of non-peptidic low-molecular-weight CBAs.32-34 
These compounds may be good candidate CBAs for further preclinical research. 
Although peptidic lectins are currently not being evaluated in clinical trials, they 
should nevertheless be considered as valuable preclinical screening tools to find novel 
drug candidates that mimic their activity. 
UDA is a chitin-binding protein from the hevein family. It adopts a 
monomeric form in solution and is isolated from the rhizome of the stinging nettle 
(Urtica dioica, UDA) as a complex mixture of isolectins.35 With its 8.5 kDa 
molecular weight, it is one of the smallest lectins reported and it has specific GlcNAc-
binding activity.36 Two hevein domains of 43 amino acids are connected with a short 
linker of 4 amino acids in the UDA molecule. Through binding studies with GlcNAc 
oligomers it has been determined that there are presumably three sugar binding areas 
in both hevein domains meaning that a trimer of GlcNAc is the actual substrate of the 
binding site. Although the presence of a second binding site on the protein has been 
postulated by several groups, the affinity of this site for glycans would be more than 
ten-fold lower than the affinity of the first binding site.37,38 More recent studies have 
revealed that UDA isolectin I can form dimers mediated by two Zn2+ ions bound to 
the sugar binding site.39 UDA is known to be an immunomodulatory agent with 
insecticidal and fungistatic properties.40 Earlier, this agent was shown to possess 
pronounced activity against viruses such as HIV,41 HCV42 and human 
cytomegalovirus (CMV),41 with a low agglutination activity against human red blood 
cells.25,41 
We here focus on the tobacco agglutinin or NICTABA, another GlcNAc-
specific CBA, isolated from the plant Nicotiana tabacum.43 This lectin turned out to 
be a cytoplasmic/nuclear chito-oligosaccharide-binding protein whose expression is 
induced in tobacco leaves by jasmonates or stress situations such as insect attacks. It 
forms a homodimer consisting of two subunits with a dimer molecular weight of 
approximately 38 kDa. The lectin shows a strong affinity for N-acetyl-D-glucosamine 
(GlcNAc)–oligomers, but in addition also to high-mannose-type N-glycans.44 In this 
study the broad antiviral properties of UDA and NICTABA are compared and their 
mechanism of HIV-envelope interaction investigated.  
MATERIALS AND METHODS 
Compounds   
The chitin-binding lectin from stinging nettle (Urtica dioica, UDA) was purified 
using a combination of cation exchange chromatography and affinity chromatography 
on a chitin column, as described previously.35 The tobacco (Nicotiana tabacum cv 
Samsun NN) lectin NICTABA was purified from tobacco leaves treated with methyl 
jasmonate using affinity chromatography on chitin followed by anion exchange 
chromatography as described by Chen et al.43 The mannose-specific lectin 
Hippeastrum hybrid (HHA) was purified from Hippeastrum hybrid bulbs using 
affinity chromatography on mannose-sepharose, as described previously.45  The 2G12 
mAb was generously provided by Polymun Scientific (Vienna, Austria). 
 
Cell line cultures and primary leukocytes  
Human T-lymphocytic C8166, HUT-78, SupT1 and CEM cells were obtained from 
the American Type Culture Collection (Manassas, VA). MT-4 cells were provided by 
Dr. L. Montagnier (at that time at the Pasteur Institute, Paris, France). The Raji DC-
SIGN-expressing Raji/DC-SIGN cells and the TZM-bl cells46 were kindly provided 
by Dr. L. Burleigh (Institut Pasteur, Paris, France) and by Dr. G. Van Ham (ITG, 
Antwerp, Belgium), respectively. The CrFKs were obtained from Dr. H. Egberink, 
(University of Utrecht, Netherlands). Buffy coat preparations from healthy donors 
were obtained from the Blood Bank (Red Cross) in Leuven, Belgium. Peripheral 
blood mononuclear cells (PBMCs) were activated with phytohaemagglutinin (PHA) 
at 2 µg/mL (Sigma, Bornem, Belgium) for 3 days at 37°C before further use in 
antiviral assays as PHA-activated PBMCs. All cell lines mentioned were cultivated in 
RPMI-1640 medium supplemented with 10% FBS (BioWittaker Europe, Verviers, 
Belgium), 2 mM L-glutamine and 0.075 M NaHCO3. 
HIV strains 
HIV-1 (IIIB) was provided by Dr. R.C. Gallo and Dr. M. Popovic (Institute of Human 
Virology, University of Maryland, Baltimore, MD). HIV-2 (ROD) was provided by 
Prof. L. Montagnier (at that time at the Pasteur Institute, Paris, France). The primary 
clinical isolates representing different HIV-1 clades and HIV-2 isolates were all 
kindly provided by Dr. J. Lathey from BBI Biotech Research Laboratories, Inc., 
Gaithersburg, MD, and their co-receptor use (R5 or X4) was determined in our 
laboratory.47 
 
Antiviral assays 
The antiviral assays were based on the inhibition of virus-induced cytopathicity in 
confluent cell cultures, and the cytostatic assays on inhibition of cell proliferation in 
exponentially growing cell cultures according to previously described 
methodology.48,49 The antiviral assays, other than the anti-HIV assays, were based on 
the inhibition of virus-induced cytopathicity in HEL [(HSV-1) (KOS), HSV-2 (G), 
Vero (parainfluenza-3), HeLa (coxsackie virus B4, reovirus-1 and respiratory 
syncytial virus), CrFK (feline coronavirus and herpes virus) or MDCK [influenza A 
(H1N1, H3N2) and influenza B] cell cultures. Confluent cell cultures (or nearly 
confluent for MDCK cells) in microtiter 96-well plates were inoculated with 100 
times the median cell culture infective dose (100 CCID50) of virus, and the cell 
cultures were incubated in the presence of varying concentrations of the compounds. 
Viral CPE was recorded as soon as it reached completion in the control virus-infected 
cell cultures that were not treated with the compounds. The minimal cytotoxic 
concentration (MCC) of the compounds was defined as the compound concentration 
that caused a microscopically visible alteration of the cell morphology. For the 
antiviral assay with dengue virus (DENV), the Raji/DC-SIGN+ cells were infected 
with DENV serotype 2 in absence or presence of the CBAs and analyzed by flow 
cytometry 4 days post-infection, as described previously.50 
 
Anti-HIV replication assays  
The methodology of the anti-HIV assays was as follows: human CEM (∼ 3 x 105 
cells/cm3) cells were infected with 100 CCID50 of HIV-1 (IIIB) and seeded in 200 µL 
wells of a microtiter plate containing appropriate dilutions of the lectins. After 4 days 
of incubation at 37 °C, HIV-induced CEM giant cell formation was examined 
microscopically. The antiretroviral assays in MT-4 cells and T-cell blasts have been 
described in detail earlier.51 Briefly, MT-4 cells (1 x 106 cells/mL) were pre-incubated 
for 30 minutes at 37°C with the test compounds in a 96-well plate. Next, NL4.3 virus 
was added according to the CCID50 of the viral stock. CPE was scored 
microscopically 5 days post-infection, and the 50% effective concentration (EC50)-
values were determined using the MTS/phenazine ethosulfate (PES) method.51 
The PHA-stimulated blasts were seeded at 0.5 x 106 cells per well into a 48-well plate 
containing varying concentrations of compound in medium containing interleukin 
(IL)-2 (25 U/mL, R&D Systems Europe, Abingdon, UK). After 30 minutes of pre-
incubation with the test compounds, 1,000 pg/mL virus stock (HIV-1, HIV-2, clinical 
isolates) was added. At day 3 and 6 post-infection 2 ng/mL IL-2 was once more 
supplemented to the cells. Cell supernatant was collected at day 10 and HIV-1 core 
antigen (Ag) in the culture supernatant was analysed by a p24 Ag ELISA kit (Perkin 
Elmer, Zaventem, Belgium) according to manufacturers’ guidelines. For HIV-2 p27 
Ag detection the INNOTEST from Innogenetics (Temse, Belgium) was used.  
TZM-bl cells were seeded at a density of 17 x 104 cells/well in a 96-well plate and 
were pre-incubated with varying concentrations of compounds at 37°C. After the pre-
incubation step, stock of BaL virus was added at a final concentration of 500 pg/mL 
and incubated for an additional 48 hrs. Luminescence was measured after 10 min 
incubation with Steadylite Plus Reagent (Perkin Elmer). To determine loss in cell 
viability, luminescence from the sample-treated wells were compared to that of the 
cell controls. EC50 is reported as the concentration of the sample which reduced the 
relative luminescence units (RLUs) by 50% compared to the virus control.  
 
Effect of NICTABA or UDA on giant cell formation in co-cultures of Sup T1 
cells with persistently HIV-1-infected HUT-78/HIV-1 cells (Giant cell assay). 
Persistently HIV-1-infected HUT-78 cell cultures were generated as described 
previously.24 For the co-cultivation assays HUT-78/HIV-1 cells were thoroughly 
washed to remove free virus from the culture medium, and 5 x 104 cells (50 µL) were 
transferred to 96-well plates. Then, a comparable amount of Sup T1 cells (50 µL), 
along with an appropriate concentration of test compound (100 µL), was added to 
each well. After 2 days, the EC50-values were determined microscopically based on 
the appearance of syncytia in the cell co-cultures. 
 
Effect of short exposure of HIV-1 to test compounds on virus capture by 
Raji/DC-SIGN cells (HIV-1 capture assay). 
High amounts of HIV-1 particles (100 µL; 2.2 x 106 pg p24/mL) were exposed to 
serial dilutions of the compounds (400 µL) for 30 min as described before.13 Then, the 
drug-exposed virus suspensions (500 µL) were mixed with Raji/DC-SIGN+ cell 
suspensions (500 µL; 106 cells) for 60 min at 37 °C after which the cells were 
thoroughly washed twice with 40 mL culture medium as described above. This 
procedure resulted in a final dilution of the initial compound concentrations by at least 
160,000-fold. The Raji/DC-SIGN+ cell cultures were then analysed for p24 Ag 
content. 
Exposure of DC-SIGN+ cells to HIV-1 and subsequent co-cultivation with CD4+ 
T cells (HIV-1 Transmission assay). 
The B-lymphocyte Raji DC-SIGN-expressing (Raji/DC-SIGN+) cells were suspended 
in cell culture medium at 6 x 106 cells/400 µL as described by Balzarini et al.13 
Briefly, 0.4 mL-cell suspensions were exposed to 600 µL wild-type HIV-1 (IIIB or 
HE) (2.2 x 106 pg/mL p24) for 60 min, after which the cell-virus suspension was 40-
fold diluted in culture medium. After centrifugation at 1,250 rpm for 10 min, the 
obtained pellet was resuspended in a large volume of medium. Following a second 
centrifugation step, supernatant was once more removed and the remaining 0.1 mL 
cell suspension was 10-fold diluted in cell culture medium. Under these experimental 
(washing) conditions, a maximum of 8 pg HIV-1 p24 could have remained in the 1 
mL-supernatant (or 0.4 pg in 50 µL). A 50 µL cell suspension was withdrawn for p24 
Ag determination by a specific HIV-1 p24 ELISA and 50 µL of the Raji/DC-SIGN+ 
cell suspension was added to 96-well microplates in which 100 µL compound 
dilutions were present. Then, 50 µL C8166 cells (107/mL) were added to each well. 
These mixed cell cultures were incubated at 37°C in a CO2-controlled humidified 
incubator, and microscopically scored for syncytia formation at ~ 36 to 48 hrs post 
virus-exposure/co-cultivation. It should be mentioned that the maximum amount of 
free viral particles that could have remained in the culture medium after extended 
washing steps (< 1 pg HIV-1 p24) is unable to result in HIV-1-induced giant cell 
formation in CD4+ T cell cultures within the time period of analysis (36 to 48 hours). 
 
2G12 mAb binding  assay.  
CD4+ MT-4 cells were infected with HIV-1 NL4.3 and analysed when the CPE 
started to occur (3-4 days post-infection). Shortly, after washing with PBS 
supplemented with 2% FCS (PBS/FCS2%), the cells were pre-incubated with various 
concentrations of NICTABA, HHA or UDA for 30 minutes, extensively washed and 
incubated with 2G12 mAb for 30 minutes. Afterwards, the cells were washed and 
further incubated with RaH-IgG-FITC (Dako) for 30 minutes. As a control for non-
specific background staining, the cells were stained in parallel with RaH-IgG-FITC 
only. After washing, the cells were fixed with a 1% aqueous formaldehyde solution 
and analysed with a FACSCalibur flow cytometer using Cell Quest software (BD 
Biosciences, San Jose, CA, USA). For the calculations of the mAb binding, the mean 
fluorescence intensity (MFI) of each sample was expressed as percentage of the MFI 
of control cells (after subtracting the MFI of the background staining).  
 
Surface Plasmon Resonance   
1) Kinetic experiments  
For the HIV envelope binding experiments, the recombinant glycoprotein gp120 from 
the HIV-1 IIIB strain (ImmunoDiagnostics Inc., Woburn, MA; produced in cell 
cultures of chinese hamster ovaries) and the recombinant glycoprotein gp41 from the 
HIV-1 HxB2 strain (Acris Antibodies GmbH, Herford, Germany; produced in P. 
pastoris cells) were covalently coupled to the carboxymethylated dextran matrix-
covered CM5 sensor chips at flow channels two and four, respectively, (GE 
Healthcare, Uppsala, Sweden) in 10 mM sodium acetate, pH 4.0 using the standard 
amine coupling chemistry affording a final density of 148 RUs for gp120 (1.25 fmol) 
and 265 RUs for gp41 (6.5 fmol). The flow cells in channels one and three were used 
as controls for non-specific binding and refractive index changes.  
All interaction studies were performed at 25 °C on a Biacore T100 instrument (GE 
Healthcare, Uppsala, Sweden). The compounds were diluted in HBS-P (10 mM 
HEPES, 150 mM NaCl and 0,05% surfactant P20; pH 7.4) supplemented with 10 mM 
Ca2+, using two-fold dilution steps. UDA and NICTABA were used at concentrations 
ranging from 1.0 to 63 nM. Samples were injected during 3 minutes at a flow rate of 
30 µL/min followed by a dissociation phase of 5 minutes. The sensor chip was 
regenerated with 50 mM NaOH. Several blanks were included throughout the 
experiment as a second reference.  
For the determination of the kinetic parameters, the curves were fitted using the 1:1 
binding model (Biacore T100 Evaluation software 2.0.1). 
 
2) Inhibition of the binding by sugars  
The sensor surface that was prepared in 1) was used to analyse the binding of UDA 
and NICTABA in the presence or absence of a GlNAc trimer (GlcNAc β-(1,4)- 
GlcNAc/β-(1,4) GlcNAc) (Dextra Laboratories Ltd, Reading, UK), a mannose/α-
(1,2)- mannose/α-(1,2) mannose trisaccharide (Carbohydrate Synthesis, Oxford, UK) 
or a mannose/α-(1,3)-mannose/α-(1,6)-mannose trisaccharide (Dextra Laboratories 
Ltd, Reading, UK). The concentration of UDA was kept constant at 100 nM 
throughout the whole experiment. NICTABA was used at a concentration of 80 nM. 
The concentrations of the trisaccharides were 200 or 100 µM. The lectins, 
trisaccharides or a pre-incubated mixture of lectin and trisaccharide were injected 
across the sensor surface as described for the kinetic experiments. 
RESULTS 
Broad antiviral activity profile of NICTABA and UDA in cell cultures 
NICTABA and UDA have been evaluated for their inhibitory activity against 
a wide variety of enveloped DNA and RNA viruses in cell culture using the α(1,3)-
α(1,6)-mannose-specific HHA as a control (Table 1). Whereas HHA was only 
inhibitory against influenza A and B viruses, Dengue virus serotype 2 (DENV-2), and 
HIV (Table 2), the GlcNAc-specific CBAs displayed a much broader antiviral 
spectrum. They not only inhibited the same viruses as HHA did, but in addition, they 
also showed inhibitory activity against HSV type 1 (HSV-1) and HSV-2, varicella-
zoster virus (VZV) and parainfluenza virus. NICTABA often showed an activity 
superior to UDA. Interestingly, respiratory syncytial virus (RSV) and HSV-1 were 
only suppressed by NICTABA but not by UDA (Table 1). None of the three CBAs 
displayed antiviral activity to non-enveloped viruses such as coxsackie virus and 
reovirus. The median cytotoxic concentration (CC50-)value of NICTABA in HEL 
cells was >50 µg/mL (> 1.5 µM).  
 
Broad-spectrum anti-HIV activity profile of NICTABA and UDA  
Our first set of experiments demonstrated a broad activity spectrum of the 
CBAs against enveloped viruses, which are heavily glycosylated. Since HIV is one of 
the most glycosylated viruses, we evaluated the antiviral activity of CBAs and their 
mode of action against different HIV strains.  
In this part of the study, we measured the activity of NICTABA and UDA against cell 
line-adapted HIV-1 strains (NL4.3, BaL, IIIB) in different cell models including the 
genital epithelial cells TZM-bl but also susceptible CD4+ T cell lines such as MT-4 
and CEM cells. As a reference we compared the activity of the GlcNAc-binding 
lectins with the mannose-specific CBA HHA. As shown in Table 2, both NICTABA 
and UDA could inhibit infection of these HIV strains with an EC50 in the lower µM-
range (EC50: 0.023 µM – 0.28 µM).  
Secondly, the anti-HIV activity of NICTABA and UDA was tested against clade B 
HIV-1 strains and HIV-2 in PHA-activated PBMCs (or T cell blasts). We found that 
both CBAs inhibited infection of the CXCR4-using (X4) NL4.3, the CCR5-using 
(R5) BaL and the dual-tropic HE HIV-1 strains in the lower nM range (IC50 
NICTABA: 14 nM – 18 nM). Moreover, NICTABA and UDA prevented HIV-2 
infection of PBMCs with a mean EC50 of 5 and 60 nM, respectively. Overall, the 
mannose-specific lectin HHA showed a better antiviral activity against HIV-1 
laboratory strains compared to both GlcNAc-binding CBAs, but NICTABA 
demonstrated less variability in its virus-suppressive potential and was 10- to 100-fold 
more potent than UDA (Table 2).  
Thirdly, primary HIV-1 clinical isolates representing different HIV-1 clades (A, B, C, 
and A/E) were tested for their susceptibility to neutralization by NICTABA and UDA 
in PBMCs. Both CBAs were found to be protective but the neutralization activity of 
NICTABA was higher than that of UDA with EC50s varying from 8 to 30 nM. In 
addition, the antiviral activity of NICTABA was evaluated in monocyte-derived 
macrophages (MDM) against the HIV-1 BaL strain and was found to be protective 
with a mean EC50 of 0.016 ± 0.004 µM (data not shown). The CC50-value for 
NICTABA obtained in PBMCs was 0.38 µM. We can conclude that NICTABA and 
UDA exhibited a consistent and broad anti-HIV activity in both CD4+ T-lymphoma 
cell cultures and in PBMCs (Table 2). In all cases, the antiviral potency of the 
GlcNAc-binding agent NICTABA was superior to that of UDA.  
 
NICTABA and UDA inhibit HIV induced cell-cell syncytium formation 
When NICTABA and UDA were examined for their inhibitory potential to 
prevent syncytium formation between persistently HIV-1 IIIB-infected cells (HUT-
78/IIIB) and uninfected CD4+ SupT1 cells, both CBAs inhibited giant cell formation 
to a similar extent (IC50s: 0.32-0.48 µM) but inferior to the mannose-specific HHA 
(0.08 µM) (Table 3). 
NICTABA and UDA have also been investigated for their potential to prevent 
HIV-1 capture by DC-SIGN-expressing Raji/DC-SIGN+ cells and to block 
transmission of DC-SIGN-captured virus to CD4+ T-lymphocyte C8166 cell cultures. 
Whereas NICTABA could not prevent virus capture by Raji/DC-SIGN+ cells, UDA 
could do so. However HHA was much more efficient than UDA in preventing virus 
capture (Table 4). On the other hand, transmission of HIV-1-captured virus by 
Raji/DC-SIGN+ cells to the uninfected CD4+ T cells was dose-dependently inhibited 
by both NICTABA and UDA (Table 4). 
 
Effect of NICTABA, UDA and HHA on the binding of the carbohydrate binding 
mAb 2G12 to HIV-1 infected MT-4 cells. 
NICTABA at the highest concentration tested (0.52 µM; 20 µg/mL) had no 
effect on the binding of the carbohydrate-binding mAb 2G12 to HIV-1-infected MT-4 
cells, while HHA (0.4 µM; 20 µg/mL) and UDA (2.4 µM; 20 µg/mL) efficiently 
inhibited this process (Figure 1). Thus NICTABA, in contrast to all the other CBAs 
examined so far including the mAb 2G12, does not interact with the 2G12 mAb 
binding epitope on gp120. 
In addition, NICTABA, but also the other CBAs HHA and UDA at similar 
concentrations, had no effect on the binding of the mAb (clone 9205) recognizing the 
V3 loop of gp120, to HIV-1-infected MT-4 cells (data not shown). 
 
Kinetic interactions of NICTABA and UDA with the HIV envelope glycoproteins 
gp120 and gp41. 
The binding of NICTABA and UDA to the virus envelope was kinetically 
characterized by means of surface plasmon resonance (SPR) analysis. In this 
experiment, gp120 and gp41 were covalently immobilised on a CM5 sensor chip. The 
CBAs UDA and NICTABA were used as analytes in a concentration range of 1.8 to 
63 nM for NICTABA, 2.0 to 63 nM (gp120) or 2.0 to 31 nM (gp41) for UDA. The 
analyte solutions were injected across the sensor chip for 3 minutes after which the 
analyte was allowed to dissociate from the surface during 5 minutes. The residual 
analyte was then removed from the surface by using a pulse of 50 mM NaOH. The 
binding curves of NICTABA and UDA to gp120, together with the fitted curves, are 
shown in Figure 2A.  
The kinetic parameters that were determined for the binding of NICTABA and 
UDA to gp120 and gp41 are summarized in Table 5. Both CBAs showed KD 
(affinity)-values for HIV-1 gp120 in the lower nanomolar range (KD: 4-9 nM). 
Whereas the on-rates (ka) to gp120 were fairly comparable for UDA and NICTABA, 
the dissociation rate constant (kd) for NICTABA was 6-fold lower than for UDA.  
Their affinities for gp41 were at least as good as, if not better than for gp120 
(Figure 2B, Table 5). Comparable apparent KD-values (1.5-1.6 nM) were detected for 
the binding of both CBAs to gp41. For UDA the KD value was 5.4-fold lower (higher 
affinity) for gp41 than for gp120 (Table 5).  
Overall, the sensorgrams show that both CBAs have a high affinity for the 
envelope proteins gp120 and gp41 with KD values ranking in the subnanomolar range.  
 
Effect of carbohydrate oligomers on the binding of NICTABA and UDA to HIV-
1 gp120.  
To verify the nature of the sugar specificity of both lectins, the binding 
capacity of NICTABA and UDA to immobilised gp120 was investigated in the 
presence or absence of different glycan structures such as a GlcNAc β-
(1,4)/GlcNAc/β-(1,4) GlcNAc, a mannose α-(1,2)-mannose/α-(1,2)-mannose or a 
mannose/α-(1,3)-mannose/α-(1,6)-mannose oligosaccharide. 
Prior to the gp120 binding, the CBAs were incubated in the presence of the 
respective trisaccharides (trisaccharides at a final concentration of 100 or 200 µM) for 
a short time period. The GlcNAc trimer and the α-(1,2)/α-(1,2) mannose and the α-
(1,3)/α-(1,6) mannose trimers were also injected in the absence of the CBAs at a 
concentration of 200 µM as a reference. The final concentrations of NICTABA and 
UDA in these experiments were 80 and 100 nM, respectively. The results are shown 
in Figure 3.  
The binding of NICTABA to gp120 was dose-dependently reduced by the 
addition of the GlcNAc trimer to the NICTABA solution, while the other two 
mannose-trisaccharides only had a minor, if any, effect on the binding of NICTABA 
to immobilised gp120 (Figure 3A). Instead, the binding of UDA to gp120 could be 
reduced by adding either one of the trisaccharides, although the highest level of 
inhibition could be observed with the trimer of GlcNAc. Clearly, both mannose 
trimers interfered with the binding of UDA to gp120 although to a lesser extent 
compared to the effect of GlcNAc trimers on UDA binding (Figure 3B).  
DISCUSSION  
Many viruses affecting human health use the host cell machinery to assemble 
glycans on their surface, which are important for viral entry and escape from the host 
immune system.8,9,52 Glycans are bound by natural ligands called lectins that have 
differential binding preferences for them. Targeting viral glycans is a promising 
antiviral strategy since there are multiple glycosylated sites on the virus capsid.53,54 In 
addition, emergence of resistance to such anti-carbohydrate therapies will most likely 
involve the removal of multiple sugar residues from the viral envelope thereby more 
efficiently exposing the surface of the virus to host-derived neutralizing 
antibodies.25,53,55-58 Moreover, Balzarini et al.25 demonstrated that the kinetics of 
resistance development also likely depend on the type of glycan targeted as it took a 
3-fold longer time before phenotypic resistance became apparent against UDA, a 
GlcNAc-binding CBA, than against mannose-specific CBAs. Here, we evaluated the 
activity of a tobacco plant lectin called NICTABA that has exclusive affinity for 
GlcNAc residues and compared it with UDA and the mannose-specific HHA.  
We found that NICTABA and UDA are both inhibitory against a very broad 
spectrum of enveloped viruses. Interestingly, this spectrum is much broader than that 
of HHA. This may be due to the fact that GlcNAc is more abundantly present in 
complex-type than in high-mannose-type glycans. As HIV is one of the most heavily 
glycosylated viruses,59,60 we evaluated the activity of NICTABA, UDA and HHA to a 
variety of HIV strains in different target cells. Indeed, Raska et al.61 reported that the 
glycosylation pattern is profoundly influenced by the cell type and metabolic activity 
of the producing cells, resulting in distinct gp120 N-glycan contents and 
heterogeneity. While such high variability of the HIV envelope compromises the 
efficacy of neutralizing antibodies (that only recognize one specific envelope 
epitope),62 GlcNAc-specific CBAs maintained their antiviral activity with EC50-
values ranking between the lower nano- and micromolar ranges. Furthermore, 
NICTABA and UDA were endowed with much less variation in their antiviral 
spectrum than HHA. An important contributing factor to these differences may again 
be the sugar specificity of these CBAs. While HHA predominantly recognizes α-
(1,3)- and/or α-(1,6)-mannose residues located at the pentasaccharide core, GlcNAc 
oligomers are invariably present at the base of the pentasaccharide core in each N-
glycosylation site of gp120. Also, there was a clear tendency for NICTABA to be 
more potent in inhibiting virus replication than UDA. This may be related to a more 
pronounced binding of NICTABA to the viral envelope glycans than UDA. Indeed, 
the apparent affinity of NICTABA for HIV-1 gp120 was 2-fold higher than of UDA, 
but, importantly, this was mainly due to the contribution of the off-rate, which was 
∼6-fold lower for NICTABA than UDA.  
The affinity measurements between gp120 and NICTABA or UDA showed 
low KD values being in the low to sub-nanomolar range. Since the dissociation rates 
of these CBAs were very low, they can be virtually considered to be irreversible 
gp120 binders. These tight-binding properties are in agreement with the increased 
antiviral activities upon pre-incubation of HIV-1 or HIV-1-infected cells with 
NICTABA and UDA. However, Doores et al found that the glycan composition of 
recombinant monomeric gp120 mainly comprises complex glycans while the 
envelope proteins of intact virions almost exclusively carry oligomannose glycans.63 
This difference in composition may affect the binding capacity of CBAs and therefore 
our comparative binding studies performed with recombinant monomeric gp120 
needs to be interpreted with some caution and in close connection with the antiviral 
cell culture data. It was interesting to notice that the affinity of the CBAs for gp41 
(KD: ±1.5 nM) was higher than for gp120 (KD: 3.8-8.7 nM) while the envelope 
protein gp120 contains 6-fold more sites for N-linked glycosylation than gp41, which 
typically contains only 4 sites for N-glycan attachment.64  
Many viruses including HIV,65 RSV,66 and VZV67 induce membrane fusion 
between cells to form giant multinucleated cells, called syncytia, which allows the 
virion to kill many cells by just infecting one single cell. NICTABA and UDA were 
able to inhibit syncytium formation between persistently HIV-1-infected T cells and 
uninfected CD4+ T cells, thus suggesting an inhibitory role of GlcNAc-binding CBAs 
during attachment of gp120 to cellular receptors and subsequent fusion steps. This is 
an important property of the CBAs that is shared with other HIV entry inhibitors 
(dextran sulphate (DS-5000),68 enfuvirtide69 or the CXCR4 antagonists47), but is 
absent in drugs that target a site in the replication cycle of HIV located at a timepoint 
after viral entry. 
DC-SIGN is a lectin of our innate immune system predominantly present on 
immature DCs. It functions in DC recognition and the uptake and processing of 
pathogens leading to antigen presentation to T cells. It has been shown that DC-SIGN 
can recognize and internalize numerous bacteria, protozoa70 and viruses such as 
HIV,70 Dengue virus,71 human CMV,72 HCV73 and Ebola virus74 to allow for efficient 
trans infection of the target cells. Preventing interaction with DCs, and in particular 
DC-SIGN, represents an attractive approach to prevent viral transmission and 
infection of the host. We showed that UDA but not NICTABA efficiently prevents 
the DC-SIGN-directed capture of HIV-1. Interestingly, both NICTABA and UDA 
prevented transmission of DC-SIGN-captured HIV-1 to uninfected CD4+ T-
lymphocytes in the same concentration range needed for inhibition of cell-free viral 
transmission in T-lymphoma cell lines (EC50 NICTABA ~140 nM, UDA ~600 nM). 
Some CBAs have been shown to be not equally effective in their inhibitory potential 
for both modes of transmission.14,47 NICTABA is the first CBA reported so far that 
does not block DC-SIGN-directed HIV capture. This suggests that NICTABA 
recognizes different glycan epitopes than DC-SIGN, while UDA, at least partially, 
shares certain glycan epitopes present on gp120 or hinders DC-SIGN binding. Several 
studies have revealed that the carbohydrate-recognition domain of DC-SIGN 
recognizes α-(1,3)- and α-(1,2)-linked mannose oligomers75 as well as fucosylated 
glycans.76 That NICTABA prevented HIV-1 transmission but not viral capture could 
be explained by the assumption that its binding to the GlcNAc-containing glycans on 
gp120 prevents conformational changes and hinders the flexibility of gp120 that is 
required to properly interact with the cell membrane receptor necessary for fusion.  
When taking a closer look at the results of the sugar inhibition experiments, it 
is clear that the binding of NICTABA and UDA to gp120 in the presence of a 
GlcNAc β-1,4-trimer was dose-dependently decreased. This is in line with previous 
reports on the GlcNAc specificity of both lectins. While this appears to be in contrast 
to the recent finding from a microarray screen that NICTABA also efficiently 
recognizes high-mannose glycans,77 it should be mentioned that these studies found 
high affinity of GlcNAcβ1,4GlcNAc configurations that are extended with mannose 
residues. This may imply that NICTABA shows a certain affinity for mannose 
oligomers on the condition that they are part of a complex with GlcNAc oligomers. 
Generating crystal structures with (GlcNA)2Manx oligomers might be useful to clarify 
this observation. 
In this report, α-(1,2)-mannose and α-(1,3/1,6)-mannose trimers (devoid of 
GlcNAc residues) hardly influenced NICTABA binding but they did affect UDA 
binding to gp120, albeit to a lesser degree than in the presence of GlcNAc 
trisaccharides. This finding suggests that UDA has a high affinity for GlcNAc 
residues but, like DC-SIGN, can also recognize α-(1,3)- and α-(1,2)-linked mannose 
oligomers. Another observation that supports the broader sugar specificity of UDA is 
that binding of the monoclonal antibody 2G12 is diminished in the presence of UDA 
but not of NICTABA. 2G12 mAb is one of the few broadly neutralizing anti-HIV 
monoclonal antibodies that solely recognizes a specific configuration of three α1,2-
mannose glycan oligomers on gp120, which lies around the C4-V4 region.78-80 
2G12 mAb activity has been shown to vary depending on the nature of the 
HIV-1 isolates that are evaluated. Indeed, Travers et al.58 has demonstrated that the 
2G12 epitope is poorly conserved across the HIV-1 group M due to strong strain-
specific glycosylation patterns. In this report, the observed narrow variation in the 
potency of NICTABA represents an interesting property with respect to the potential 
use for NICTABA as an antiviral agent. Furthermore, Huskens et al.15 observed that 
under increased drug pressure from the 2G12 mAb, HIV-1 became resistant rather 
quickly (6 cell culture passages) and only one glycan deletion appeared sufficient for 
the 2G12 mAb to lose its antiviral activity. This observation was also confirmed in 
vivo where the potency of 2G12 and two other neutralizing antibodies to gp41 were 
evaluated in HIV-1 infected individuals.81 Although plasma levels of 2G12 were the 
highest and exceeded the in vitro required 90% inhibitory doses, viral escape emerged 
very rapidly and at high titers.81 In contrast, only after more than 90 cell culture 
subcultivations did a UDA-resistant virus emerged possessing 9 mutations at N-linked 
glycosylation sites.25 Interestingly, more high mannose glycan-containing 
glycosylation sites were deleted compared with complex mannose-type glycans of 
gp120.25 Complex N-linked glycans differ from the high-mannose and hybrid glycans 
by having added other sugars including GlcNAc residues at both the α-3 and α-6 
mannose sites. Cross-resistance was observed with multiple mannose-specific CBAs 
(HHA, GNA, CV-N, 2G12).25 It would be of interest to see if NICTABA-resistant 
virus would have a similar preference for annihilation of high mannose type N-
glycans in gp120 than for complex N-linked glycans. However, after 70 
subcultivations no phenotypical and genotypical resistance of HIV-1 was observed 
against the GlcNAc-specific NICTABA (data not shown). Unfortunately, due to a 
limited selectivity index (SI=21) in cell culture, we will probably not be able to 
increase drug pressure and thus generate an HIV-1 resistant NICTABA strain.  It has 
been shown that certain lectins can induce a mitogenic response, for instance 
cyanovirin, which despite being a very potent inhibitor of viral entry, can bind to the 
host cell surface, induce T-cell activation markers and production of various pro-
inflammatory cytokines.82 In contrast, griffithsin one of the most potent CBAs 
identified to date, has also been shown to bind the host cell surface but this binding 
did not result in cellular activation.82 Whether NICTABA also binds to the cell 
surface remains unclear, since there are currently no specific antibodies available to 
resolve this issue. 
A better understanding of the molecular interaction between NICTABA and 
the GlcNAc-sugar residues on gp120 by NMR or crystallography would enable 
rational design of more potent synthetic GlcNAc-specific CBAs. Further research to 
feasibly scale-up synthetic GlcNAc-specific CBAs should be explored due to the high 
genetic barrier for resistance development, even more so than for mannose-specific 
CBAs. Another concern that is often raised for CBAs in general is their potential 
inability to discriminate between pathogen and cellular glycans. Nevertheless, it has 
been shown that the three-dimensional configuration of the glycans present on 
pathogens are important for its specific interaction.14 In fact, DC-SIGN is a very good 
example of a lectin that can distinguish between pathogen-associated glycoproteins 
and cellular glycoproteins, thereby enabling a selective elimination of the pathogen. 
Furthermore, intravenous administration of UDA and the mannose-specific GNA and 
HHA to adult mice has been shown to lack toxicity.83 In addition, for UDA, it has also 
been reported that at concentrations that were substantially higher than its antiviral 
activity in cell culture, it did not agglutinate human red blood cells and was poorly 
mitogenic.25  
All things considered, targeting the envelope N-glycans of HIV and other 
viruses might be a promising strategy. This is also corroborated by the fact that a new 
generation of potent, broadly neutralizing antibodies has recently been identified from 
HIV-1-infected individuals that target novel epitopes on HIV gp120 which are partly 
or exclusively composed of glycans. 84-88 These mAbs have been shown to exhibit 
great breadth and antiviral potency against various HIV-1 isolates in vitro and showed 
promising results in a vaccination study in macaques.85 These recent findings indicate 
that CBAs may have potential as future antiviral drugs. 
In summary, NICTABA is, unlike UDA, a clearly GlcNAc-specific CBA and 
is endowed with a broad-spectrum antiviral activity. It may concomitantly suppress 
both well-known co-pathogens HIV and HSV, which is beneficial from a microbicide 
viewpoint.89 Furthermore, its neutralizing activity was striking, in the sense that 
NICTABA displayed minimal variation in antiviral activity, irrespective of the nature 
of the HIV viral strain and host cell type. In addition, NICTABA was found to be a 
potent inhibitor of syncytium formation and of DC-SIGN directed transmission to 
CD4+ T-lymphocytes. These properties together make NICTABA an appealing and 
potent candidate for further drug development against enveloped viruses. The 
therapeutic exploitation of a GlcNAc-specific CBA will require the design of 
synthetic mimics that share the same broad activity but lack the potential cellular side 
effects of NICTABA.  
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Table 1. Antiviral activity of NICTABA, UDA and HHA against a broad spectrum of 
viruses evaluated in HEL, MDCK, HeLa, Raji DC-SIGN, CrFK or Vero cell cultures.  
 
aIC50 (50% inhibitory concentration): the concentration to inhibit virus-induced CPE by 50%.  
b Molecular weight of NICTABA: 38 kDa, UDA: 8.5 kDa, HHA: 50 kDa 
MCC (minimal cytotoxic concentration) for NICTABA (µg/ml): HEL > 100, HeLa > 100, 
Vero > 100 
CC50 (median cytotoxic concentration) for NICTABA (µg/ml): MDCK > 50, CrFK > 50, 
Raji/DC-SIGN+ > 50 
ND: not determined 
Mean IC50 ± SEM from 3-4 independent experiments are shown 
  
Viruses  
 
EC50a (nM) 
NICTABAb UDAb HHAb 
ENVELOPED VIRUSES    
Herpes simplex virus-1 (KOS) (HEL) 263 ± 113 > 11800 > 2000 
Herpes simplex virus-2 (G) (HEL) 53 ± 11 1294 ± 82 > 2000 
Herpes simplex virus-1 TK- KOS ACV (HEL) 171 ± 47.0 9647 ± 3764 > 2000 
Varicella-zoster virus (HEL)  129 ± 1.32 ND ND 
Influenza A H1N1 subtype (MDCK) 32 ± 11 506 ± 153 540 ± 360 
Influenza A H3N2 subtype (MDCK) 18 ± 5.3 188 ± 47 2 ± 0.2 
Influenza B (MDCK) 11 ± 0.0 224 ± 176 6 ± 2 
Parainfluenza-3 virus (HeLa) 50 ± 26 235 ± 0.0 > 2000  
Respiratory syncytial virus (HeLa) 105 ± 0.0 > 11800 > 2000 
Dengue virus Type 2 (Raji/DC-SIGN+) 526 ± 2.3 1176 ± 423 12 ± 0.2 
Feline Herpes virus (CrFK) 
 
24 ± 0.3 647 ± 470 220 ± 86 
Feline Corona virus (CrFK) 153 ± 1.7 1024 ± 106 520 ± 12 
NON-ENVELOPED VIRUSES    
Coxsackie virus B4 (HeLa) > 2600 > 5900 > 2000 
Reovirus-1 (Vero) > 2600 > 11800 > 2000 
Table 2. Anti-HIV activity (EC50 in µM) of NICTABA, UDA and HHA against 
laboratory-adapted strains and clinical isolates of HIV in cell cultures and PHA-
activated PBMCs 
HIV-1 strains (tropism; subtype) NICTABA UDA HHA 
Laboratory-adapted strains    
MT-4/NL4.3 (X4; B) 0.17 ± 0.08 0.28 ± 0.08¶ 0.004 ± 0.001¶ 
TZM-bl/BaL (R5; B) 0.23 ± 0.05 0.5 ± 0.1 0.010 ± 0.001 
CEM/IIIB (X4; B) 0.023 ± 0.003 0.23 ± 0.00 0.0060 ± 0.0005 
PBMCs/NL4.3 (X4; B) 0.018 ± 0.003 0.23 ± 0.06 0.005 ± 0.002 
PBMCs/BaL (R5; B) 0.014 ± 0.005 0.38 ± 0.14 0.01 ± 0.004 
PBMCs/HE (X4/R5; B) 0.015 ± 0.004 1.80 ± 0.02 0.240 ± 0.039 
PBMCs/ROD (HIV-2) 0.005 ± 0.003 0.06 ± 0.03 NDa 
Clinical isolates    
PBMCs/UG273 (R5; A) 0.008 ± 0.002 1.6 ± 0.7 NDa 
PBMCs/DJ259 (R5; C) 0.020 ± 0.004 0.1 ± 0.2 0.10 ± 0.02 
PBMCs/ID12 (R5; A/E) 0.010 ± 0.003 0.4 ± 0.2 NDa 
PBMCs/ETH2220 (R5; C) 0.03 ± 0.01 0.8 ± 0.3 NDa 
PBMCs/US2 (R5; B) 0.03 ± 0.03 NDa NDa 
aND: not determined. 
¶Data obtained from Huskens et al.17   
CC50 for NICTABA (µg/ml): MT-4 > 20, TZM-bl > 20, CEM > 20, PBMCs: 14.4  
Mean EC50-values ± SEM from at least 3-5 independent experiments are shown. 
Table 3. Inhibitory activity of NICTABA, UDA and HHA against syncytia formation 
between persistently HIV-1-infected cells and uninfected CD4+ T cells. 
 
CBA EC50a (µM) 
NICTABA 0.32 ± 0.09 
UDA 0.48 ± 0.1 
HHA 0.08 ± 0.02 
aEC50: The effective concentration of CBA necessary to inhibit syncytia formation between persistently 
HIV-infected HUT-78/IIIB cells and uninfected CD4+ SupT1 T cells by 50%.  
Mean EC50-values ± SEM of 3 independent experiments are shown. 
Table 4: Inhibition of HIV-1 capture and transmission by DC-SIGN+ cells to human 
CD4+ T-lymphocytes. 
 
CBAs 
EC50a (µM) 
Capture Transmissionb 
NICTABA >1.3 0.14 
UDA 0.44 0.61 
HHA 0.01 0.06 
a EC50: The effective concentration of CBA necessary to inhibit HIV-1 capture by Raji DC-SIGN and 
the transmission of DC-SIGN-captured virus to uninfected CD4+ C8166 T cells by 50%. 
b In co-cultivation cultures with CD4+ C8166 T cells, samples were taken 44 hours post co-cultivation.  
Table 5: Kinetic parameters of the interaction of NICTABA and UDA with 
immobilised HIV-1 envelope proteins gp120 and gp41 determined through surface 
plasmon resonance. 
 
HIV-1 gp 120 ka (1/Ms)a kd (1/s)a KD (M)a,b 
NICTABA 1.8 105 ± 9.3 101 7.0 10-4 ± 9.5 10-7 3.8 10-9 
UDA 4.8 105 ± 5.7 102 4.2 10-3 ± 3.5 10-6 8.7 10-9 
HIV-1 gp 41 ka (1/Ms) kd (1/s) KD (M) 
NICTABA 1.7 105 ± 6.1 102 2.6 10-4 ± 9.1 10-7 1.5 10-9 
UDA 1.0 106 ± 2.9 103 1.6 10-3 ± 3.3 10-6 1.6 10-9 
a ka: association rate constant; kd: dissociation rate constant; KD: affinity constant. 
b The affinity constant KD is the ratio kd/ka.. 
Mean values ± SEM from 3 independent experiments are shown.  
Figures 
 
Figure 1. UDA and HHA but not NICTABA inhibit the binding of the 2G12 
mAb to HIV-1 NL4.3-infected MT-4 cells.  
MT-4 cells were infected with HIV-1 strain NL4.3. After 3-4 days, the cells were 
incubated with the 2G12 mAb (20 µg/mL) + RaH-IgG-FITC in the absence (green 
curves or presence of NICTABA (red curves) or HHA (blue curves) or UDA (purple 
curves). The light grey curves show the background fluorescence. The average MFI 
values of 3 independent experiments are indicated above each histogram and reflect 
the degree of binding of the 2G12 mAb to the HIV-1 infected cells. One 
representative experiment out of three is shown. 
 Figure 2. Kinetic analysis of CBA interactions with immobilised envelope 
proteins of HIV. Binding of NICTABA (left panels) or UDA (right panels) to HIV-1 
IIIB gp120 (A) or HIV-1 HxB2 gp41 (B) immobilised on a CM5 sensor chip. Serial 
two-fold analyte dilutions were injected over the surface of the HIV-1 envelope 
protein-bound sensor chip. These dilutions covered a concentration range from 1.0 to 
63 nM for NICTABA and from 2.0 to 63 nM (gp120) or 2.0 to 31 nM (gp41) for 
UDA. Experiments were carried out in triplicate (coloured lines). The curves were 
fitted using the 1:1 binding model (black curves) to determine the kinetic parameters.  
 
 Figure 3. Affinity analysis of NICTABA (A) and UDA (B) for immobilised HIV-1 
IIIB gp120 in the presence or absence of various oligosaccharides. 
The concentrations of the trisaccharides (GlcNAc β-(1,4)-GlcNAc/β-(1,4)-GlcNAc; 
mannose α-(1,2)-mannose/α-(1,2)-mannose; mannose α-(1,3)-mannose/α-(1,6) 
mannose) were 200 or 100 µM. UDA concentration was kept constant at 100 nM and 
NICTABA at 80 nM throughout the whole experiment. The lectins, trisaccharides or a 
pre-incubated mixture of lectin and trisaccharide were injected across the sensor 
surface. 
